Targeting inflammatory cytokines-androgen receptor (AR) signaling with ASC-J9® to better battle prostate cancer progression

Macrophages inflammatory cytokines/chemokines in prostate cancer (PCa) microenvironment may go through androgen receptor (AR) signaling to influence PCa progression: macrophages induce tumorigenesis by the alteration of AR-CCL4 signaling and can be interrupted by AR-degradation enhancer ASC-J9. Androgen deprivation therapy with anti-androgens enhances CCL2-pSTAT3 signaling to promote metastasis and ASC-J9 can inhibit CCL2-pSTAT3 signaling to suppress PCa metastasis. Targeting inflammatory cytokines-AR signaling with ASC-J9 may become a promising therapy to battle PCa in future.

[1]  Chawnshang Chang,et al.  Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling. , 2013, Cancer research.

[2]  Chawnshang Chang,et al.  Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation , 2013, EMBO molecular medicine.

[3]  S. Yeh,et al.  Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling , 2013, Cell Death and Disease.

[4]  Chawnshang Chang,et al.  Androgen receptor roles in the development of benign prostate hyperplasia. , 2013, The American journal of pathology.

[5]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[6]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[7]  Chawnshang Chang,et al.  Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression. , 2009, The Journal of clinical investigation.

[8]  Howard Y. Chang,et al.  Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Crawford,et al.  Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials , 2000, The Lancet.

[10]  Chang George.  Androgen Receptor Is a Tumor Suppressor and Proliferator in Prostate Cancer , 2009 .